The global biological safety testing products & services market size was estimated at USD 4.89 billion in 2024 and is projected to reach USD 12.09 billion by 2033, growing at a CAGR of 10.64% from 2025 to 2033. The market growth is primarily driven by the rising prevalence of target diseases and the increasing production of next-generation biologics by biotechnology and pharmaceutical companies. These trends have intensified the demand for robust biological safety testing processes to ensure the quality, efficacy, and safety of therapeutic products.

The growing global demand for biologics has led to a significant rise in the number of biopharmaceutical companies, intensifying competition among manufacturers to develop effective and affordable therapeutic drugs at scale. This competitive environment has prompted companies to enhance industrial processes for greater productivity and cost efficiency. For example, in July 2023, Biocon Biologics, an India-based firm, launched Humira, a biosimilar version of AbbVie’s rheumatoid arthritis drug, in the U.S. market at a lower price point, making it widely accessible across the region. To maintain high quality and safety standards, several organizations are adopting improved manufacturing practices that incorporate rigorous biological safety testing throughout multiple stages of production, thereby fueling market growth.

The continuous expansion of the biopharmaceutical and biotechnology industries serves as a major growth catalyst for the biological safety testing products and services market. The increasing global development of biologics, biosimilars, cell and gene therapies, and regenerative medicines is creating a strong need for accurate, validated biosafety testing solutions. As regulatory frameworks become more stringent and therapeutic pipelines expand, companies are investing substantially in testing infrastructure, technological innovation, and strategic collaborations to meet the biosafety requirements of evolving biologic modalities. Additionally, rising capital investments, mergers, and platform advancements across the globe are further contributing to the market’s robust and sustained growth trajectory.

Key Market Trends & Insights:

• North America dominated the global biological safety testing products and services market, accounting for the largest share of 36.59% in 2024. The region’s leadership can be attributed to the strong presence of established biopharmaceutical and biotechnology companies, advanced healthcare infrastructure, and favorable regulatory frameworks that emphasize product safety and quality. Furthermore, the continuous introduction of innovative biologics, vaccines, and cell and gene therapies, coupled with increasing R&D investments, has further strengthened the region’s market position.

• Within North America, the U.S. market is expected to experience significant growth over the forecast period. This growth is driven by the country’s expanding biopharmaceutical manufacturing capabilities, high healthcare expenditure, and supportive government initiatives aimed at ensuring biologic product safety. Additionally, the growing focus on developing novel therapeutics, the presence of leading industry players, and the rising adoption of advanced biosafety testing technologies contribute to the market’s strong outlook in the U.S.

• Based on product, the reagents and kits segment held the largest market share of 39.69% in 2024. The dominance of this segment is attributed to their widespread use across various biological testing processes, including mycoplasma testing, endotoxin testing, sterility testing, and residual host contamination analysis. The increasing need for high-quality, reliable, and easy-to-use reagents and kits to ensure accurate test results has further driven segment growth.

• In terms of application, the vaccines and therapeutics segment accounted for the highest market share in 2024. The rising demand for vaccines and biotherapeutic drugs, especially following the global emphasis on preventive healthcare and pandemic preparedness, has led to greater adoption of biological safety testing services to ensure product efficacy and patient safety.

• By test type, the endotoxin tests segment dominated the market in 2024. This can be attributed to the critical role endotoxin testing plays in identifying bacterial contaminants in biologics and pharmaceutical products. With strict regulatory guidelines requiring endotoxin testing for product release, the demand for advanced, rapid, and highly sensitive endotoxin detection assays continues to rise, supporting the segment’s strong market presence.

Order a free sample PDF of the Biological Safety Testing Products And Services Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 4.89 Billion

• 2033 Projected Market Size: USD 12.09 Billion

• CAGR (2025-2033): 10.64%

• North America: Largest market in 2024

• North America: Largest market in 2024

Key Companies & Market Share Insights:

Market leaders in the biological safety testing products and services industry are heavily investing in research and development (R&D) activities to design and produce cost-effective, technologically advanced, and highly reliable testing products. Their focus on innovation aims to enhance testing accuracy, efficiency, and scalability to meet the evolving needs of the biopharmaceutical and biotechnology sectors. These continuous R&D efforts are also directed toward the development of next-generation testing platforms that ensure compliance with stringent regulatory standards while optimizing operational performance.

In addition to R&D initiatives, leading companies are actively adopting various strategic approaches—such as mergers, acquisitions, collaborations, and partnerships—to strengthen their market presence and expand their service portfolios. Such strategies allow them to gain access to advanced technologies, broaden their global reach, and enhance their expertise in specialized areas of biosafety testing.

For example, in January 2023, Charles River Laboratories, Inc. acquired SAMDI Tech, Inc., a company specializing in high-throughput screening (HTS) solutions used in diverse drug discovery research applications. This acquisition has significantly enhanced Charles River Laboratories’ capabilities in providing comprehensive drug discovery and development services. By integrating SAMDI Tech’s innovative HTS technology with its existing portfolio, the company has reinforced its position as a key provider of end-to-end research and biosafety testing solutions, thereby creating substantial growth opportunities for the future.

Key Players

• Charles River Laboratories

• BSL Bioservice

• Merck KGaA (MilliporeSigma)

• Samsung Biologics

• Sartorius AG

• Eurofins Scientific

• SGS Société Générale de Surveillance SA

• Thermo Fisher Scientific Inc.

• BIOMÉRIEUX

• Lonza

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global biological safety testing products and services market is expected to witness robust growth, driven by the increasing production of biologics, biosimilars, cell and gene therapies, and vaccines that require stringent safety validation. Rising regulatory standards, growing focus on contamination control, and expanding outsourcing to specialized testing providers are key factors propelling the market. Advancements in testing technologies, such as automation, high-throughput screening, and next-generation sequencing, are enhancing accuracy and efficiency.